Moreover, among untreated advanced NSCLC patients who were selected based on a PD‐L1 expression level of ≥50% on tumor cells, treatment with anti‐PD‐1 antibody (pembrolizumab) conferred a higher response rate of about 45% and a longer PFS and OS, compared with platinum‐based chemotherapy.6 This evidence concerns the gene CD274 and non-small cell lung carcinoma.